MARKET

PVLA

PVLA

Palvella Therapeutics Inc
NASDAQ
85.66
+3.33
+4.04%
After Hours: 83.95 -1.71 -2.00% 19:45 02/20 EST
OPEN
81.89
PREV CLOSE
82.33
HIGH
85.95
LOW
78.17
VOLUME
277.41K
TURNOVER
--
52 WEEK HIGH
114.69
52 WEEK LOW
17.31
MARKET CAP
1.01B
P/E (TTM)
-22.3842
1D
5D
1M
3M
1Y
5Y
1D
Palvella Therapeutics COO Kathleen Goin Disposes of Common Shares
Reuters · 6h ago
Palvella Therapeutics (PVLA) Gets a Buy from Craig-Hallum
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: Aethlon Medical (AEMD), Humana (HUM) and Palvella Therapeutics (PVLA)
TipRanks · 3d ago
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Palvella Therapeutics (PVLA)
TipRanks · 4d ago
Weekly Report: what happened at PVLA last week (0209-0213)?
Weekly Report · 4d ago
Analysts’ Top Healthcare Picks: Cogstate Ltd (COGZF), Palvella Therapeutics (PVLA)
TipRanks · 02/12 22:40
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Palvella Therapeutics (PVLA)
TipRanks · 02/09 16:10
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Progyny (PGNY)
TipRanks · 02/09 15:20
More
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Webull offers Palvella Therapeutics Inc stock information, including NASDAQ: PVLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PVLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PVLA stock methods without spending real money on the virtual paper trading platform.